Lupin Pharmaceuticals, Inc. announced that the FDA approved its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Oral Solution, offering a cost-effective alternative for pain management. This approval strengthens the company's portfolio and increases accessibility to essential opioids in the generic market.